Key Takeaways
- Volume-led growth, margin hit by input costs: Domestic formulations grew 8% YoY (15% ex-COVID base) driven by volume, but gross margin fell ~5 percentage points as raw material and packing material inflation bit.
- Price hike lagged, relief expected in Q2: A 10%+ WPI-linked price hike on scheduled formulations became effective only partially in Q1; full impact should be visible by end of Q2, promising margin recovery if input costs cooperate.
- Exports surged on US supplies: Export formulations jumped 42% YoY, led by increased US shipments, and management expects the growth trajectory to continue.
- Brand concentration strategy is working: All Top 10 brands are growing double digits, with Electral climbing the IPM ranks and Enerzal positioned as the next ₹200-crore brand.
- What to watch next quarter: Whether the full price hike flows through to gross margins as promised, any further movement in raw material costs, and if the seasonal Q2 antibiotic peak delivers the "very promising" quarter management expects.
Margin Walk: The Inflation Squeeze and the Price-Hike Antidote
- Gross margin down ~5 pp: The decline, worth ~₹34 crores in absolute terms, was purely on account of elevated raw material and packing material prices. Management declined to split the impact between the two components.
- Price hike realization was partial: Only ~50% of products carried the increased price in Q1 because pipeline inventories from the March quarter were still being sold through. For major brands Electral and Zifi, the price rise became effective only from May and June.
- Q2 margin recovery expected, but not quantified: Goods sold in Q2 will be almost purely from Q1 inventory carrying the increased sales price, so margins should improve sequentially. Management refused to quantify the improvement, citing uncertainty on further raw material and packing material cost movements.
- Other costs also climbed: Sales and marketing spend rose from ~6.75% to 8% of revenue YoY, partly due to a new division launch and partly due to lumpy accounting of promotional material receipt. Logistics costs added another half a percentage point of pressure.
- One-off provision distorts opex: A temporary ₹15 crore mark-to-market provision on financial instruments inflated other expenses; this has since been reversed. The remaining ~₹20 crore YoY opex increase was driven by higher sales and marketing, production, and logistics costs.
Sanjay Jain: "The exact quantification we will not be able to do as of now, but I can give you a broad guidance on that considering the fact the goods which have been sold in the Q1 are partially from the carry forward of the March quarter inventory and partially from the Q1 inventory. Now whatever inventory which are going to be get sold in the Q2 almost purely of a Q1 inventory means the inventory with the increased sales price. So, with this increase sales price the margins will obviously improve in the Q2 as compared to Q1 margin but having said this we also have to wait and watch any further impact on the raw material and packing material."
Domestic Formulations: Volume Engine, Brand Focus
- Real growth was ~15% ex-COVID: Reported 8% YoY growth was weighed down by a high base that included ~₹17 crores of low-margin Favipiravir trading sales in Q1 FY22. Stripping that out, underlying growth was healthy and volume-led at 7.6%, with price contributing 2.1% and new products 1.8%.
- Top 3 brands did the heavy lifting: Zifi, Electral, and Enerzal were the major growth contributors, and all Top 10 brands are growing in double digits. Electral moved up to 34th rank in IPM on a MAT June '22 basis, from 37th.
- New Zocon division launched: A dedicated derma division was carved out of existing Proxima and Lumina divisions, adding ~400 people. This, plus the annual appraisal cycle, kept employee costs at ~20% of revenue while absolute spend rose.
- New launches are minimal, deliberate: Recent introductions are mainly line extensions of existing brands like Electral and EnteroPlus sachets; no new molecule set-ups were entered. Management is consolidating around the Top 10 brands and will push new launches only once recent expansions stabilize.
- Q2 seasonality is a tailwind: Q2 is normally the highest-potential quarter because antibiotic sales peak; management called it "very promising" for all top three brands. Q3 is the leanest as antibiotic and ORS/energy drink sales dip.
Mayank Tikkha: "Again, we are planning in nice fashion. We are very aggressive but as I said that all these plans are plans till the times you don't get the execution right and also the results right. But yes, the trends are very encouraging. We have continued good run."
Exports: US-Led Surge, Profit Share Normalizes
- 42% YoY export growth: The jump was largely on account of increased supplies to US customers, apart from other markets. Revenue rose ~₹7 crores YoY.
- FY21 profit share was an anomaly: Competitors exited the Timolol Maleate eyedrops market in FY21, creating a one-off profit share windfall. Management was explicit that hitting that same profit share number in FY23 is "very challenging," though the underlying sales base ex-profit-share can use FY21 as a reference.
- Margins currently attractive: Export margins are favorable, particularly from the US business. Management cautioned that as volumes grow, margins can vary by market and are being watched closely.
- Growth trajectory expected to continue: When asked if export growth would sustain for the rest of the year, management answered "by and large yes."
Ameya Chandavarkar: "So, yes, from a sales perspective excluding profit share you can use FY21 as a base but what happened in FY21 in terms of profit share was an anomaly. So, that's really why this year we find it very challenging to hit that same profit share number."
Capital Allocation & Investments
- Ophthalmic CAPEX of ₹70–80 crores: Investment is planned for expanding one ophthalmic line at the Waluj plant. Management declined to provide any guidance on asset turns or top-line expectations, saying it will share details once available.
- Buyback completed: A buyback of ~₹170 crores was announced in March '22. On future buybacks, management said it cannot comment as of now and will update if anything materializes.
- ANDA filing: An ANDA application for Olopatadine Hydrochloride ophthalmic solution 0.2% was filed during the quarter.
- Disclosure upgrade promised: Management committed to providing a geographical breakup of revenues (India, US, other exports, API) on a quarterly basis, benchmarking against peers.
Pricing Strategy & NLEM Dynamics
- WPI-linked hike on ~45% of domestic portfolio: A 10% plus sales price increase was taken on scheduled formulations. For major brands Electral and Zifi, the price rise became effective from May and June, so Q1 captured only a partial benefit. Full visibility is expected by end of Q2.
- NLEM price increase of 10.7%: Full impact will be seen in Q2 FY23, as new-priced product may not have been in the pipeline during Q1.
- Non-NLEM pricing is opportunistic: Price increases on non-NLEM products are taken on a 12-month rolling basis wherever the competitive scenario allows. Management said it is difficult to comment on an average percentage on a quarterly or YoY basis.
- Price hikes flow to the bottom line: Increases on scheduled formulations go directly to the bottom line unless offset by further raw material or packing material price increases.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Price hike visibility | Full impact of 10%+ WPI-linked price hike on scheduled formulations visible | End of Q2 FY23 |
| NLEM price hike impact | Full impact of 10.7% NLEM increase reflected in financials | Q2 FY23 |
| Gross margin recovery | Margins to improve in Q2 vs. Q1 as goods sold carry increased sales price, subject to no further raw material cost increases | Q2 FY23 |
| Export growth | Growth trajectory expected to continue for the rest of the year | FY23 |
| Geographical revenue disclosure | Quarterly breakup of revenues by India, US, other exports, API | Starting from a future quarter |
| Ophthalmic CAPEX guidance | Asset turn and top-line expectations to be shared | No date (once available) |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Overall revenue growth | 11% YoY |
| Domestic formulation growth | 8% YoY, against a high base of 68% growth in Q1 FY22; real growth excluding COVID products would have been ~15% |
| Export formulation revenue growth | 42% YoY (standalone) |
| API business revenue growth | 25% YoY (standalone) |
| Revenue growth break-up | 11.5% overall, volume growth 7.6%, price growth 2.1%, new product growth 1.8% |
| EBITDA margin | 20%, compared to 31% in Q1 FY22 |
| Gross margin impact from raw and packing material | ~5% of revenue, absolute impact of ₹34 crores |
| Employee cost | ~20% of revenue, slightly lower than Q1 FY22 |
| Sales and marketing expenses | ~8% of revenue, compared to ~6.75% in Q1 FY22 |
| Fair value impact on financial instruments | ₹15 crores temporary provision, reversed post-quarter with market rebound |
| PBT | ₹90 crores, compared to ₹127 crores in Q1 FY22 |
| Domestic formulation sales | ₹423 crores (out of ₹493 crores total revenue) |
| NLEM portfolio price increase | 10.7% taken; NLEM portfolio is ~45% of domestic formulation business |
| Medical Representative count | 3,615 as of June, up from ~3,242 in March, addition of ~400 for new Zocon division |
| Cash on books | ~₹750 crores |
| CAPEX planned for ophthalmic line | ₹70–80 crores at Waluj plant |